Vaccine Leadership The Duke Human Vaccine Institute is positioned as a national and international leader in vaccine research, with a focus on addressing bottlenecks for HIV, influenza, and SARS-CoV-2. This presents sales opportunities for contract research services, translational science support, assay development, and access to specialized immunology platforms, alongside potential multi-year sponsored programs with government or philanthropic funders.

Strategic Partnerships DHVI's involvement in the Global HIV/AIDS Vaccine Enterprise and biodefense research indicates strong potential for co-development, sponsored research, technology licensing, and pilot studies with pharma, biotech startups, and academic consortia. Opportunities exist to align with grant opportunities, joint ventures, and shared R&D initiatives.

AI Data Enablement Recent coverage of an AI framework development at Duke highlights openness to data-driven approaches. This creates opportunities to offer AI/ML consulting, data management, high performance computing, and predictive modeling services for vaccine discovery, optimization of study designs, and decision support in research programs, including integration with existing tools like LabVIEW and OnBase.

Lab Informatics DHVI's tech stack includes OnBase and LabVIEW, indicating mature digital workflows. There is potential to provide lab automation, instrument control, electronic lab notebook integration, workflow optimization, data capture, and secure content management solutions that improve research efficiency and compliance.

Mid-sized Scale With 51-200 employees and substantial but not enterprise-scale revenue, DHVI represents a mid-sized research organization suitable for multi-year contracts, equipment and software procurement, professional services, and scalable program support across vaccine and biodefense initiatives.